Should You Buy the Dip in These 2 Dividend Stocks?

Group 1 - The proposal for near-flat Medicare Advantage reimbursements combined with a rising medical care ratio has created uncertainty for U.S. health insurers, which previously relied on this segment for profits [1] - Independent studies indicate that Medicare Advantage offers greater value than traditional Medicare, with lower costs for the federal government and reduced out-of-pocket expenses for enrollees, influencing market perceptions of companies involved in this sector [2] - Humana (HUM) and CVS Health (CVS) have seen stock declines following revised expectations for Medicare Advantage profitability, raising questions about whether this represents a buying opportunity or a sign of capped returns [3] Group 2 - Humana, based in Louisville, Kentucky, focuses on Medicare Advantage and related coverage, offering an annualized dividend of $3.54 per share, yielding 1.34% at current stock levels [4] - Humana's stock is trading at $195.14, down 24% year-to-date and 34% over the past 52 weeks, reflecting a market value of approximately $25 billion and trailing earnings of 13.93 times, compared to a sector median of 17.98 times [5] - A leadership change at Humana includes the retirement of long-time insurance chief George Renaudin and the appointment of Amazon veteran Aaron Martin as president of Medicare Advantage, with a transition planned through 2026 [6] Group 3 - Humana's third-quarter 2025 results showed GAAP net income of $195 million, or $1.62 per share, with adjusted EPS of $3.24, exceeding the consensus estimate of $2.91 by $0.33, indicating strong underlying operations despite cost pressures [7]